Contents
1. Our Lane & What We Are Not
DB Marketing LLC operates solely as a chemical supplier. We market, brand, and facilitate orders for research-grade peptides and small molecules intended for laboratory study. Independent third-party suppliers and laboratories manufacture, package, and ship the physical products under commercial arrangements with Aflu.
To be unambiguous about what Aflu is not:
- Aflu is not a compounding pharmacy or chemical compounding facility (Section 503A), nor are we an outsourcing facility (Section 503B) under the Federal Food, Drug, and Cosmetic Act.
- Aflu is not a telehealth provider. We do not employ or contract with prescribing clinicians and do not issue prescriptions.
- Aflu is not a dietary supplement brand. Our products are not formulated, labeled, or intended for human ingestion under DSHEA.
- Aflu is not a drug manufacturer. We do not file ANDAs, INDs, or NDAs and do not market FDA-approved drug products.
- Aflu products are not intended to diagnose, treat, cure, mitigate, or prevent any disease or condition in humans or animals.
2. The Four Pillars
Our compliance posture rests on four operating pillars that we apply to every product, page, ad, and partner relationship.
Research-Use Framing
Every compound is sold as a research reference material. Product pages, dosage information, and study citations exist for informational and research purposes only — never as medical guidance, prescribing instruction, or use-case recommendation.
Gated Access
Every visitor passes through an age-verification and research-use certification gate before reaching catalog pricing or checkout. The certification is timestamped and recorded with each order as part of an express assumption-of-risk waiver.
No Claims, No Outcomes
We do not make therapeutic, diagnostic, weight-loss, performance, anti-aging, or any other outcome claims in product descriptions, marketing, advertising, or affiliate material. We describe what compounds have been studied, never what they will do for a buyer.
Transparent Sourcing
Every product is third-party tested, with a certificate of analysis available on request. We disclose our supplier-relationship structure in our Terms and operate without hidden compounding-pharmacy or telehealth-clinic relationships.
3. Legal Framework
Aflu's research-supply model operates under the following legal posture, which our Terms of Service and Research Use Disclaimer implement in full:
- Research-use-only certification. Buyers contractually certify, at the gate and again at checkout, that products are for laboratory research only and not for human or veterinary use.
- Express assumption of risk. Buyers sign a binding waiver releasing Aflu and its suppliers from liability arising from any misuse, regardless of the buyer's stated intent at purchase.
- 21+ age verification. No buyer under 21 is permitted to complete a purchase.
- Geographic restriction enforcement. Aflu does not ship to jurisdictions that prohibit the purchase or use of research peptides; buyers warrant they are not located in such a jurisdiction.
- Mandatory disclaimers. Every product page and every marketing surface carries the line "For research use only. Not intended for human consumption."
- Mandatory arbitration and Utah governing law. Disputes are resolved through binding arbitration in Utah, with a one-year time-limit on claims.
4. FDA Category Notes & Catalog Curation
The FDA maintains a list of bulk drug substances that may be used in compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Many research peptides have been on or near the agency's Category 2 list, which restricts compounding for human administration pending further review.
On April 22, 2026, the FDA removed twelve peptides from Category 2 — including BPC-157, TB-500, KPV, MOTS-c, CJC-1295, Ipamorelin, Epitalon, Selank, Semax, DSIP, Kisspeptin-10, LL-37, Thymosin Alpha-1, and topical GHK-Cu — after the original nominating compounders withdrew their submissions. These compounds are now in regulatory limbo: not restricted, but not yet formally cleared for compounding. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review four of these (BPC-157, KPV, MOTS-c, TB-500) at its July 23–24, 2026 meeting, with the remaining peptides scheduled for review by February 2027.
None of this affects Aflu's research-supply model. The Category 2 framework governs compounding for human Rx use — a lane Aflu does not operate in. Our catalog is curated against a separate, stricter internal standard:
- We include compounds with established research-supply history, third-party-testable purity, and stable molecular characterization.
- We exclude active pharmaceutical pipeline assets owned by major drug sponsors (where research-supply sales create sponsor-enforcement risk).
- We exclude FDA-approved prescription products for which a research-use lane is not legally recognized.
- We exclude Schedule I–V controlled substances, narcotics, and any compound whose possession is restricted under the Controlled Substances Act.
- We exclude any compound where credible safety data is absent and a research-use frame cannot reasonably be defended.
5. What We Do Not Sell & Why
Catalog curation is an active discipline. Compounds removed from the Aflu catalog as of the date of this page include:
- Survodutide, Mazdutide, Retatrutide (and related GLP-pipeline tri-agonists). Active pharmaceutical pipeline assets owned by Boehringer Ingelheim, Eli Lilly, and Innovent. Sponsor-enforcement risk is high and growing; not appropriate for research-supply distribution.
- HCG (Human Chorionic Gonadotropin). FDA-approved prescription drug (brand names Pregnyl, Novarel, Ovidrel). Research-use framing is not a recognized lane for this compound.
- HMG (Human Menopausal Gonadotropin). FDA-approved prescription drug (brand names Menopur, Repronex). Same reasoning as HCG.
- Injectable GHK-Cu specifically. Topical GHK-Cu was removed from Category 2 on April 22, 2026; injectable GHK-Cu remains on Category 2 and cannot be legally compounded for injection under any compounding-pharmacy lane. Aflu sells GHK-Cu as a research reference material without specifying route of administration.
- All Schedule I–V controlled substances and all DEA-scheduled compounds.
- Anabolic-androgenic steroids and SARMs. Selective androgen receptor modulators and AAS are not included in the Aflu catalog.
- Compounded GLP-1 medications for human Rx use. Aflu does not sell semaglutide, tirzepatide, or liraglutide formulated for human prescription dispensing. The FDA's proposed exclusion of these compounds from the 503B bulks list is being actively litigated; Aflu does not operate in that lane.
This list is reviewed and updated as the regulatory landscape evolves.
6. Quality & Sourcing Standards
Aflu requires the following from every supplier relationship:
- Certificate of Analysis on every batch, available to buyers on request.
- Third-party purity testing conducted independently of the manufacturing supplier.
- HPLC and mass-spec characterization for peptide identity verification.
- Cold-chain handling where required by the compound's stability profile.
- Lot traceability from manufacturing through fulfillment.
- US-based fulfillment for all retail orders.
7. Marketing & Affiliate Standards
Aflu's marketing and affiliate program operates under the same compliance posture as the catalog itself. We do not:
- Make outcome or benefit claims in advertising (no "lose weight," "build muscle," "anti-aging," "performance enhancement," etc.).
- Use clinical verbs (no "treat," "cure," "prescribe," "diagnose," "heal," "prevent").
- Display before-and-after body imagery or transformation claims in paid creative.
- Permit affiliates to share personal dosing stories, before-and-afters, or any content that frames the products as personal-use supplements or medicines.
- Name specific compounds in paid advertising creative on platforms whose policies prohibit it.
- Run ads that target audiences under 21.
Affiliates receive a written compliance brief at onboarding and are subject to removal for non-compliance.
8. Buyer Verification & Gating
Every visitor encounters a compliance gate on first session that requires:
- Confirmation of age 21 or older;
- Certification that all purchases are for laboratory research use only;
- Acknowledgement of the Research Use Disclaimer.
At checkout, the certification is repeated as a signed consent checkbox tied to the order record. Each order is associated with a timestamped record of the certifying buyer, the IP address of the certification, and the version of the Terms in force at the time of order.
9. Ongoing Monitoring
Aflu actively monitors:
- FDA bulk-drug-substance list updates (503A and 503B).
- Pharmacy Compounding Advisory Committee meeting agendas and outcomes.
- FDA warning letters issued to research-supply, compounding, and telehealth peers.
- Pharmaceutical-sponsor enforcement actions (cease-and-desist trends).
- State pharmacy board guidance and state-level peptide rules.
- DEA scheduling actions on emerging compounds.
- Ad platform policy updates (Meta, Google, TikTok) affecting peptide/research-supply category.
Catalog and policy changes resulting from this monitoring are reflected on this page and in the underlying Terms of Service.
10. Contact
Compliance questions, regulatory inquiries, and good-faith reports of non-compliant marketing or affiliate behavior:
DB Marketing LLC
Email: team@aflu.com
Orders: orders@aflu.com
This page describes Aflu's operating posture and is provided for transparency. It is not legal advice, does not create any contractual obligation beyond what is set forth in the Terms of Service, and is subject to revision as the regulatory landscape evolves. The Terms of Service and Research Use Disclaimer govern the legal relationship between Aflu and its buyers.